BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TQC3721 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TQC3721\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07464587-1558@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:TQC3721: Phase 3 readout est. (NCT07464587)
DESCRIPTION:TQC3721\, phase 3\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate
 -to-Severe Chronic Obstructive Pulmonary Disease\nEstimated primary comple
 tion: February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tqc3721#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07464587
URL:https://assetmemo.bio/drug/tqc3721#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07147946-1558@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:TQC3721: Phase 3 readout est. (NCT07147946)
DESCRIPTION:TQC3721\, phase 3\, Chronic Obstructive Pulmonary Disease.\nStu
 dy: Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Pati
 ents With Moderate-to-Severe Chronic Obstructive Pulmonary Disease\nEstima
 ted primary completion: March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tqc3721#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07147946
URL:https://assetmemo.bio/drug/tqc3721#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
